Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis

ClinicalTrials.gov ID: NCT02494479

Public ClinicalTrials.gov record NCT02494479. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double Blind, Parallel Group, Placebo Controlled Clinical Study of the Efficacy and Safety of Three Different Daily Dosages of Prurisol Administered Orally to Subjects With Active Mild to Moderate Chronic Plaque Psoriasis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is designed to evaluate the efficacy and safety of Prurisol using three different oral daily dose regimens administered to subjects with active mild to moderate chronic plaque psoriasis.

Study identification

NCT ID
NCT02494479
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Cellceutix Corporation
Industry
Enrollment
115 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2015
Primary completion
Mar 31, 2016
Completion
Apr 30, 2016
Last update posted
Jul 18, 2017

2015 – 2016

United States locations

U.S. sites
9
U.S. states
4
U.S. cities
8
Facility City State ZIP Site status
Cellceutix Study Center Huntsville Alabama 35801
Cellceutix Study Center Encino California 91436
Cellceutix Study Center Coral Gables Florida 33134
Cellceutix Study Center Hialeah Florida 33016
Cellceutix Study Center Kissimmee Florida 34741
Cellceutix Study Center Miami Florida 33126
Cellceutix Study Center Miami Florida 33144
Cellceutix Study Center Pembroke Pines Florida 33026
Cellceutix Study Center Las Vegas Nevada 89119

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02494479, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 18, 2017 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02494479 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →